Altered airway epithelial cell specification in COPD

Gohy, Sophie; Fregimilicka, Chantal; Detry, Bruno; Bouzin, Caroline; Weynand, Birgit; Pilette, Charles

doi:10.1183/13993003.congress-2015.pa924

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is critical in innate immunity against pathogens and allergens, which trigger the following inflammatory processes. In some studies, this is critical for the onset and exacerbation of asthma and COPD (Gohy et al, 2015;Ladjemi et al, 2018). By interacting with AECs, FGF family members, mostly FGF7 and FGF10, are involved in innate immunity directly and indirectly (Wu et al, 2011;Gardner et al, 2016;Yuan et al, 2019).…”

Section: Airway Epithelial Cellsmentioning

confidence: 99%

FGF2, an Immunomodulatory Factor in Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Tan

Qiao

Chen

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The fibroblast growth factor 2 (FGF2) is a potent mitogenic factor belonging to the FGF family. It plays a role in airway remodeling associated with chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). Recently, research interest has been raised in the immunomodulatory function of FGF2 in asthma and COPD, through its involvement in not only the regulation of inflammatory cells but also its participation as a mediator between immune cells and airway structural cells. Herein, this review provides the current knowledge on the biology of FGF2, its expression pattern in asthma and COPD patients, and its role as an immunomodulatory factor. The potential that FGF2 is involved in regulating inflammation indicates that FGF2 could be a therapeutic target for chronic inflammatory diseases.

show abstract

Section: Airway Epithelial Cellsmentioning

confidence: 99%

FGF2, an Immunomodulatory Factor in Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Tan

Qiao

Chen

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Pathological changes in COPD include airway wall thickening, goblet cell hyperplasia, and an increased fractional volume of bronchial epithelial cells 17 , 18 . Bronchial epithelial cells are particularly vulnerable to the effects of CS, as they are some of the first cells exposed to external particulate matter and irritants 19 .…”

Section: Introductionmentioning

confidence: 99%

Phosphate induces inflammation and exacerbates injury from cigarette smoke in the bronchial epithelium

Bollenbecker

Heitman

Czaya

et al. 2023

Sci Rep

View full text Add to dashboard Cite

An elevation in serum phosphate—also called hyperphosphatemia—is associated with reduced kidney function in chronic kidney disease (CKD). Reports show CKD patients are more likely to develop lung disease and have poorer kidney function that positively correlates with pulmonary obstruction. However, the underlying mechanisms are not well understood. Here, we report that two murine models of CKD, which both exhibit increased serum levels of phosphate and fibroblast growth factor (FGF) 23, a regulator of phosphate homeostasis, develop concomitant airway inflammation. Our in vitro studies point towards a similar increase of phosphate-induced inflammatory markers in human bronchial epithelial cells. FGF23 stimulation alone does not induce a proinflammatory response in the non-COPD bronchial epithelium and phosphate does not cause endogenous FGF23 release. Upregulation of the phosphate-induced proinflammatory cytokines is accompanied by activation of the extracellular-signal regulated kinase (ERK) pathway. Moreover, the addition of cigarette smoke extract (CSE) during phosphate treatments exacerbates inflammation as well as ERK activation, whereas co-treatment with FGF23 attenuates both the phosphate as well as the combined phosphate- and CS-induced inflammatory response, independent of ERK activation. Together, these data demonstrate a novel pathway that potentially explains pathological kidney-lung crosstalk with phosphate as a key mediator.

show abstract

Altered airway epithelial cell specification in COPD

Cited by 2 publications

References 0 publications

FGF2, an Immunomodulatory Factor in Asthma and Chronic Obstructive Pulmonary Disease (COPD)

FGF2, an Immunomodulatory Factor in Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Phosphate induces inflammation and exacerbates injury from cigarette smoke in the bronchial epithelium

Contact Info

Product

Resources

About